Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Nexo Therapeutics | 2023 | Series A | $60.0M | Littleton |
| Myra Vision | 2023 | Series B | $25.0M | Campbell |
| Elevation Oncology | 2023 | Post Ipo Equity | $50.0M | New York |
| connectRN | 2023 | Convertible Note | $750K | Waltham |
| Icosavax | 2023 | Post Ipo Equity | $67.8M | Seattle |
| Ventus Therapeutics | 2023 | Grant | $150K | Waltham |
| Pliant Therapeutics | 2023 | Post Ipo Equity | $287.5M | South San Francisco |
| BlissBio | 2023 | Series B | $14.8M | Hangzhou |
| Tricida | 2022 | Post Ipo Debt | $125.0M | Menlo Park |
| Kezar Life Sciences | 2022 | Post Ipo Equity | $12.2M | South San Francisco |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 101 | Nexo Therapeutics | Series A | $60.0M | Littleton, United States |
| 102 | Myra Vision | Series B | $25.0M | Campbell, United States |
| 103 | Elevation Oncology | Post Ipo Equity | $50.0M | New York, United States |
| 104 | connectRN | Convertible Note | $750K | Waltham, United States |
| 105 | Icosavax | Post Ipo Equity | $67.8M | Seattle, United States |
| 106 | Ventus Therapeutics | Grant | $150K | Waltham, United States |
| 107 | Pliant Therapeutics | Post Ipo Equity | $287.5M | South San Francisco, United States |
| 108 | BlissBio | Series B | $14.8M | Hangzhou, China |
| 109 | Tricida | Post Ipo Debt | $125.0M | Menlo Park, United States |
| 110 | Kezar Life Sciences | Post Ipo Equity | $12.2M | South San Francisco, United States |
Nexo Therapeutics offers treatments for some of cancer's most intractable targets.
Myra Vision develops a treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma.
Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.
ConnectRN is a tech-enabled network built to improve clinicians' lives through access to community, opportunity, and support.
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Bliss Bio is a biopharmaceutical company focused on development of tumor targeting and immunotherapy drugs.
Tricida operates in the healthcare industry focusing on pharmaceutical business.
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Axonics Modulation Technologies is a pre-revenue company developing novel implantable neuromodulation.
MOMA Therapeutics operates as a biotechnology company.
Arkuda Therapeutics is a pharmaceutical company.
Twist Bioscience is a biotechnology company that offers synthetic DNA solutions, gene synthesis, and variant libraries.
908devices manufactures battery-operated, hand-held chemical detection tools used in mass spectrometry.
Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS).
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies
Renovia was a developer of prescription digital therapeutics for pelvic floor disorders. Renovia ceased operations in late 2022.
Graphite Bio is a next-generation gene editing company that is driven to apply our breakthrough technology.
DTx Pharma is a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease.
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Turning Point Therapeutics is a pharmaceutical company that discovers and develops precision medicines for cancer and other diseases.
Cormorant Asset Management has invested in 134 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Medical. The firm invests across 20 different industry categories.
Among tracked funding rounds, Turning Point Therapeutics received $460.0M in a Post Ipo Equity round. Cormorant Asset Management's total known invested capital is $12.5B.
Cormorant Asset Management's average investment size is $116.4M across its portfolio of 134 companies.
Recent Cormorant Asset Management portfolio additions include Nexo Therapeutics, Myra Vision, Elevation Oncology, connectRN, Icosavax. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors